KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Current Leases (2021 - 2024)

BioNTech SE's Current Leases history spans 4 years, with the latest figure at $42.2 million for Q4 2024.

  • On a quarterly basis, Current Leases rose 39.61% to $42.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $42.2 million, a 39.61% increase, with the full-year FY2024 number at $42.2 million, up 39.61% from a year prior.
  • Current Leases hit $42.2 million in Q4 2024 for BioNTech SE, up from $30.2 million in the prior quarter.
  • Over the last five years, Current Leases for BNTX hit a ceiling of $42.2 million in Q4 2024 and a floor of $30.2 million in Q4 2023.
  • Historically, Current Leases has averaged $35.3 million across 4 years, with a median of $34.3 million in 2021.
  • Biggest five-year swings in Current Leases: decreased 17.68% in 2023 and later surged 39.61% in 2024.
  • Tracing BNTX's Current Leases over 4 years: stood at $31.9 million in 2021, then increased by 15.08% to $36.7 million in 2022, then decreased by 17.68% to $30.2 million in 2023, then soared by 39.61% to $42.2 million in 2024.
  • Business Quant data shows Current Leases for BNTX at $42.2 million in Q4 2024, $30.2 million in Q4 2023, and $36.7 million in Q4 2022.